As more is learned about the importance of the intestinal microbiome to human health there is increasing interest in the potential benefits of probiotics. Probiotics are live micro-organisms which, when consumed in adequate amounts, confer a health effect on the host by altering its microflora. Probiotics have been administered both prophylactically and therapeutically for various conditions. This statement definines the development and role of intestinal microflora, and examines the evidence supporting the use of different probiotics to treat common paediatric conditions, such as diarrhea, atopy, functional intestinal disorders and necrotizing enterocolitis. Recommendations to guide physicians in the judicious use of these products are offered.
This statement defines what probiotics and prebiotics are, reviews the development and role of intestinal microflora and examines evidence supporting the use of different probiotics for various childhood conditions. A literature review was conducted in English and French using Medline (1966 to 2011), the Cochrane database and relevant websites. PubMed was used to identify relevant randomized controlled trials (RCTs) and metaanalyses involving the use of probiotics in paediatrics. Physician guidance for the judicious use of these products in paediatric patients is offered.
Probiotics (eg, lactobacilli, bifidobacteria, saccharomyces) are live micro-organisms which can confer a health effect on the host when consumed in adequate amounts. They are nonpathogenic in the normal host, resist processing and are able to survive in the digestive tract. Prebiotics (eg, fructo-and galacto-oligosaccharides) are nonviable food components which can confer a health benefit on the host by modulating intestinal microflora.
Development and composition of gut microflora
Colonization of an infant's intestine begins immediately after birth. Type of delivery, the infant diet (breast milk versus formula) and other factors, such as environment, gestational age and the presence of antibiotics, influence the composition of gut microflora. Because bifidobacteria and galacto-oligosaccharides are components of breast milk, the flora of breastfed infants contain more lactobacilli and bifidobacteria than the flora of formula-fed infants. Once solid food is introduced into the diet, the composition of a child's intestinal microflora begins to resemble the adult flora.
The role of gut microflora
The gut microflora is a complex ecosystem supporting the structure and function of the intestinal mucosa. Intestinal bacteria contribute to the gut's barrier function by competing with pathogenic bacteria, increasing mucin secretion, decreasing gut permeability and modulating the gut's immune function. [1] [3] Colonic bacteria metabolize malabsorbed carbohydrates into shortchain fatty acids (SCFA). SCFA are a preferential fuel for the enterocyte; they also acidify colonic content and increase water absorption.
Using probiotics
Probiotics modify the gut microflora by lowering colonic pH through production of SCFA, by producing antimicrobial compounds and antitoxins, and by competing with other bacteria for nutrients and adhesion receptors. They also enhance gut barrier function and have a role in immunomodulation. Different strains of probiotics have different biological activities.
Preventing antibiotic-associated diarrhea
Antibiotic-associated diarrhea (AAD) is usually defined as ≥3 loose stools/day for ≥2 days occurring up to two weeks after the initiation of antibiotics. AAD occurs in about 30% of patients.
A 2002 meta-analysis which included two paediatric and seven adult studies favoured the use of probiotics, with an OR of 0.37. [4] Several paediatric RCTs using different strains of probiotics were also published [5] [12] (Table 1) , as well as two specifically paediatric meta-analyses, which showed a significant reduction of AAD using various probiotics (RR 0.47 and 0.44). The most consistently effective were Lactobacillus rhamnosus GG (LGG) and Saccharomyces boulardii. However, the number needed to treat to prevent one case of diarrhea was 10 in one meta-analysis and seven in the other. [13] [14] Consuming yogurt containing probiotics did not prevent AAD in another study. [15] While per protocol results seem to indicate that probiotics such as S boulardii and LGG decrease the incidence of AAD, the intention to treat analysis showed less impressive results, suggesting that lack of compliance may be an issue. 
Clostridium difficile
One adult study showed a 50% decrease in the relapse rate in patients with recurrent C difficile when treated with S boulardii in conjunction with antibiotics, but no benefit for those with an initial episode. [16] An adult meta-analysis found no evidence to support the use of probiotics in the treatment of C difficile. [17] To date there have been no paediatric RCTs.
While there is currently no evidence to support using probiotics either to prevent or treat C difficile in children or adults, there might be a role for probiotics in preventing relapse in patients with recurrent C difficile infection.
Treatment of acute infectious diarrhea in children
Probiotics have been used to treat acute viral diarrhea in children. Five paediatric meta-analyses showed reduced durations of diarrhea, ranging between -16.8 h and -30.0 h. [18] [22] The subgroup with rotaviral diarrhea seemed to be more responsive to probiotics [19] and LGG appeared to be the most effective probiotic [5] [12] ( Table 2) .
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Preventing infectious diarrhea
The efficacy of probiotics in preventing infectious diarrhea has been studied in multiple settings (with hospitalized patients, in child care settings and in the community) using various strains of probiotics.
LGG reduced the incidence of acute diarrhea, particularly in non-breastfed infants [23] - [26] as did S boulardii, Bifidobacterium bifidum, Lactobacillus casei, Bifidobacterium lactis, and Lactobacillus reuteri in other individual studies. [27] - [31] A combination of Bifidobacterium breve
and Streptococcus thermophilus decreased the incidence of dehydration. [32] Other studies did not show a significant decrease in the incidence of acute diarrhea [33] - [34] (Table 3 ).
There seems to be a modest effect for some probiotic strains in preventing acute diarrhea, particularly in children who are not breastfed. Probiotic use may be considered in long-term facilities or for patients attending child care who have recurrent infections. 
Irritable bowel syndrome
Alteration of the gut microflora may be implicated in the pathogenesis of irritable bowel syndrome (IBS). It is a common problem in children and treatment options are limited.
Two adult meta-analyses using various strains of probiotics found a modest improvement in symptoms. [35] [ 36] There have been four published paediatric trials.
LGG decreased abdominal distension [37] and was more likely to improve symptoms of patients with IBS than a placebo. [38] Escherichia coli decreased gassiness and bloating, and one product, VSL#3 (Seaford Pharmaceuticals, Ontario), improved IBS scores [39] [40] ( Table  4 ).
The data on IBS and probiotics are preliminary but there seems to be an effect in improving some symptoms. 
Infantile colic
The intestinal microflora may play a role in pathogenesis of colic. Lower counts of lactobacilli have been found in the intestinal flora of colicky infants. [41] [42] Two trials showed a significant reduction of crying in infants receiving L reuteri [43] [44] (Table 5) .
While there may be a role for probiotics in treating infantile colic, there is insufficient evidence to recommend for or against using probiotics to manage this condition. A recent CPS practice point on infantile colic reached the same conclusion. 
Preventing necrotizing enterocolitis
Altered intestinal permeability and intestinal bacteria may be involved in the pathogenesis of necrotizing enterocolitis (NEC). One recent study showed that a bifidobacteria-supplemented formula decreased intestinal permeability in preterm infants. [45] Studies with NEC prevention as their primary outcome are listed in Table  6 . In the first published study, LGG did not decrease the incidence of NEC significantly. [46] Subsequent studies showed that infants fed breast milk supplemented with lactobacillus and bifidobacteria had a significantly lower incidence of NEC and deaths than infants receiving unsupplemented breast milk. [47] - [49] The severity and incidence of NEC was lower in infants given a mixture of Bifidobacterium infantis, B bifidus and S thermophilus. [50] In three recent meta-analyses, enteral probiotic supplementation significantly reduced the incidence of severe NEC (RR 0.32 to 0.36) and mortality (RR 0.40 to 0.47) without systemic infection with the bacteria used as probiotics. [51] - [53] Probiotics may help to prevent NEC. Administering live microorganisms to preterm newborns should be approached with caution. Along with breastfeeding promotion, probiotics can be considered for the prevention of NEC in preterm infants >1 kg who are at risk for NEC. There is currently no data for infants weighing <1000 g. 
Traveller's diarrhea
There are no paediatric studies of probiotics in preventing traveller's diarrhea. A meta-analysis of adult trials showed a statistically significant protective effect for various probiotics (RR 0.85), [54] but most of these studies had significant limitations. No conclusions can be drawn from the literature at this time and further trials are needed.
Preventing infections
Probiotics may be useful in preventing infections, both by decreasing intestinal permeability and stimulating the immune system. In one Finnish study, children in day care centres who drank milk supplemented with
LGG experienced fewer days with respiratory and gastrointestinal symptoms, but the only outcome to reach statistical significance was the number of days of absence due to illness. [23] B lactis and S thermophilus decreased antibiotic use significantly in children attending daycare. [55] Infant formulas supplemented with B lactis and L reuteri reduced the number of episodes of fever and diarrhea, the number of medical visits, the number of days absent from child care and antibiotic use [30] in one Israeli study. Finally, infants in one community who required formula feeding under two months of age 0 | were given LGG and B lactis Bb-12. These infants had a lower incidence of otitis media and recurrent respiratory infections, and were prescribed fewer antibiotics than others who received placebo [56] (Table 7) .
Probiotics might help to reduce childhood respiratory illnesses, antibiotic use and absences from child care due to illness. However, more trials are needed before any definitive conclusions can be made. 
Preventing atopic and allergic diseases
Atopic diseases are often related to food allergies, which are more likely to develop when intestinal permeability is altered. Probiotics decrease intestinal permeability and the absorption of large molecules. This effect may help to prevent expression of an atopic constitution by diminishing allergen uptake. Lower counts of lactobacilli and bifidobacteria are found in children with atopic dermatitis compared with healthy controls. [57] In studies of children with atopic dermatitis treated with lactobacilli, a significant decrease in measures of intestinal permeability was observed, suggesting that impairments of gut barrier function in these patients can be improved with probiotics. [2] Also, gut microflora interact with gut-associated lymphoid tissue. Probiotics may influence the balance between the T H 1 and T H 2 responses and prevent the development of allergic disease.
Two RTCs suggested that LGG supplementation before delivery for pregnant mothers with a family history of atopy, and subsequent supplementation while breastfeeding or formula feeding later, reduced the risk of developing atopic dermatitis in their infants. [58] - [60] However, subsequent studies did not show such an effect. [61] - [64] A recent meta-analysis concluded that there was insufficient evidence to recommend adding probiotics to infant feeds to prevent allergic disease or food hypersensitivity [65] (Table 8) .
Despite initially encouraging results, recent studies have failed to demonstrate a beneficial effect, and further research is required. 
Treatment of atopic dermatitis
Two early probiotics studies showed promising results for the treatment of atopic dermatitis.
LGG and L reuterii were used for six weeks in children with moderate to severe eczema. While there was no significant improvement in objective disease measurements, subjects on probiotics perceived significantly more improvement than those on placebo. [66] L fermentum also diminished atopic dermatitis scores. [67] However, three subsequent meta-analyses concluded that reductions in eczema severity from probiotic treatment were modest and unlikely to be clinically significant. [68] - [70] 0 |
Treatment of allergic colitis
Using LGG as an adjunct to maternal hypoallergenic diet in breastfed infants with rectal bleeding caused by allergic colitis did not significantly affect the duration of rectal bleeding. [71] One recent study suggested that there was a greater decrease in fecal calprotectin (a marker of intestinal inflammation) and that rectal bleeding disappeared more quickly in infants treated with extensively hydrolysed formula with probiotics than with extensively hydrolysed formula alone. [72] Further studies are needed to draw conclusions at this point.
Side effects of probiotics
Some probiotics may cause systemic or local infections.
LGG and saccharomyces sepsis have been described in critically ill or immunocompromised patients, in some immunocompetent patients, and in patients with a central venous catheter. [73] - [79] There have been no reports of bifidobacterial systemic infection, and there was no increase in the incidence of lactobacilli sepsis in Finland following their introduction of lactobacilli in dairy products. [80] 
Conclusion
The literature suggests there are benefits to using probiotics for treating some diseases, such as AAD and acute infectious viral diarrhea, and to help prevent NEC. There might also be a beneficial effect in patients with colic and IBS. The role of probiotics remains unproven in preventing or treating atopic diseases. Caution should be exercised in giving probiotics to patients with an immunodeficiency. The efficacy of probiotics is both strain-and disease-specific, and any probiotic must be provided in adequate amount. Physicians need to be more aware of the differences among probiotic preparations, and government agencies should be involved in regulating the viability and composition of probiotic products. 
Recommendations
For physicians 1 . Keeping in mind that the effect of probiotics is both strain-and disease-specific, physicians should consider recommending probiotics to:
• prevent antibiotic-associated diarrhea.
• shorten the duration of acute infectious viral diarrhea.
• prevent necrotizing enterocolitis in preterm infants who are at risk of necrotizing enterocolitis.
• decrease the symptoms of colic.
• decrease some symptoms of irritable bowel syndrome.
2. Based on current evidence, the use of probiotics cannot yet be recommended for the treatment or prevention of atopic diseases.
3. Physicians should be aware of the small risks of invasive infections with using some strains of probiotics in immunocompromised patients, and more rarely in the healthy child.
4. Physicians should advocate for further research to define which strains and dose of probiotics should be used in specific conditions.
For government
The federal government should require manufacturers of probiotics and products containing probiotics to provide high quality products with precise and informative labelling.
